-
Fast Money Picks For March 7th (BMY, PGH, GM, STJ)
Friday, March 4, 2011 - 9:01pm | 208On CNBC's Fast Money, Joe Terranova advised investors to buy Bristol Myers Squibb Co. (NYSE: BMY) on Monday. Bristol Myers Squibb Co. (BMY) gained 1.11% today, and closed at $26.43. Brian Kelly recommended a long position in Pengrowth Energy Trust (USA) (NYSE: PGH). He said that it has a good...
-
Questcor Pharmaceuticals Selects BDO USA as its Auditor
Friday, March 4, 2011 - 5:07pm | 62Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) has completed a formal selection process and appointed BDO USA, LLP as its independent, registered public accounting firm for the auditing of Questcor's consolidated financial statements. Questcor has selected BDO to replace Odenberg Ullakko Muranishi...
-
Running Late 03-04-2011
Friday, March 4, 2011 - 4:43pm | 853Cusick Corner Running late today, I apologize. This is the consolidation that I had been discussing since last week, the market looks content at this stage to stay in a range, S&P 1300-1340. While this is frustrating, it is important for traders and investors to keep an eye on both volatility...
-
Puts Purchased on Repros Therapeutics Inc. (RPRX)
Friday, March 4, 2011 - 1:44pm | 125Shares of Repros Therapeutics Inc. (NASDAQ: RPRX) are higher on the session by 0.47%, currently trading at $6.39. The stock had been moving largely higher over the past four months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name...
-
How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GLD)
Friday, March 4, 2011 - 12:37pm | 437Investing and trading biotech names can be exactly like gambling, especially the smaller ones. If a company like Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Vivus (NASDAQ: VVUS), Genzyme (NASDAQ: GENZ) or Gilead Sciences (NASDAQ: GILD) or another biotech has a New Drug Application (NDA), this...
-
Puts Active as VIVUS Plunges (VVUS)
Friday, March 4, 2011 - 10:58am | 130Shares of VIVUS, Inc. (NASDAQ: VVUS) are pushing lower this morning, after the FDA warned about potential birth defects relating to its Topamax drug. Shares were down as much as 11% on the news, but have since recovered and are only lower by 4.79%, trading at $6.71. Put volume also surged on the...
-
Somaxon Reports Strong Finish To 2010, Oppenheimer Lowers PT To $8
Friday, March 4, 2011 - 10:30am | 151Oppenheimer has published a research report on Somaxon Pharmaceuticals (NASDAQ: SOMX) after the company reported its strong finish to 2010. In the report, Oppenheimer writes "On 3/3, SOMX reported 4Q10 adj. EPS of ($0.42), in line with our estimates. Importantly, revenues for 4Q10 were $1.34M,...
-
Oppenheimer Lowers PT On Somaxon Pharmaceuticals To $8
Friday, March 4, 2011 - 9:46am | 28Oppenheimer has lowered the price target on Somaxon Pharmaceuticals (NASDAQ: SOMX) from $12 to $8 and maintains its Outperform rating.
-
Pfizer Announces Primary Endpoints Met In Second Phase 3 Clinical Trial Of Tofacitinib In Patients With Active Rheumatoid Arthritis
Friday, March 4, 2011 - 9:04am | 151Pfizer Inc. (NYSE: PFE) today announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints...
-
Update: Piper Jaffray Lowering Price Target On Somaxon Pharmaceuticals (SOMX)
Friday, March 4, 2011 - 8:46am | 180Piper Jaffray is lowering its price target on shares of Somaxon Pharmaceuticals (NASDAQ: SOMX) to $5 from $7, but is keeping its Overweight rating. In a note to clients, Piper Jaffray writes, "Somaxon reported a 4Q10 net loss per share of ($0.42), slightly wider than theStreet estimate of ($0.40)....
-
Trade Ideas for Friday, March 04
Thursday, March 3, 2011 - 7:32pm | 1432( click to enlarge ) My aggressive bullish play on Pfizer Inc. (NYSE:PFE) is now open. The stock broke to new highs and hit my entry point at $19.39. My first target is $19.99. The trend since last week was "buy on dips" and today's move just confirms this fact. From the technical chart MACD...
-
Sucampo Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2010 Financial Results
Thursday, March 3, 2011 - 5:24pm | 160Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today reported its consolidated financial results for the fourth quarter and year ended December 31, 2010. In December 2010, as previously reported, SPI acquired the affiliated companies, Sucampo AG (SAG), a Swiss-based patent-holding company, and...
-
Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
Thursday, March 3, 2011 - 5:23pm | 95Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of David B. Nash, M.D., M.B.A., to the company's board of directors. Dr. Nash is the Founding Dean of the Jefferson School of Population Health at Thomas Jefferson University in Philadelphia. Dr. Nash is internationally recognized...
-
Flamel Technologies Announces Fourth Quarter and Year-End 2010 Results
Thursday, March 3, 2011 - 5:23pm | 101Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and year ended December 31, 2010. Fourth Quarter and Recent Highlights: Flamel received €3 million after achieving its first clinical milestone with Merck Serono for the development of an extended-...
-
Depomed Reports Fourth Quarter and Year-End 2010 Financial Results
Thursday, March 3, 2011 - 5:15pm | 283Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the fourth quarter and year ended December 31, 2010. "We are pleased to report a profitable year and our third consecutive profitable quarter," said Carl A. Pelzel, president and chief executive officer of Depomed. "Our excellent...